High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection

Eur J Clin Invest. 2020 Oct;50(10):e13358. doi: 10.1111/eci.13358. Epub 2020 Aug 11.

Authors

Lucia Taramasso¹, Antonio Di Biagio^{1

2}, Malgorzata Mikulska^{1

2}, Daniele Roberto Giacobbe¹, Antonio Vena¹, Chiara Dentone¹, Andrea De Maria^{1

2}, Emanuele Delfino¹, Marco Berruti², Chiara Russo², Andrea Orsi^{3

4}, Bianca Bruzzone⁴, Matteo Bassetti^{1

2}

Affiliations

¹ Infectious Diseases Clinic, Policlinico San Martino Hospital-IRCCS, Genoa, Italy.
² Department of Health Sciences, Infectious Diseases Clinic, University of Genoa, Genoa, Italy.
³ Department of Health Sciences, University of Genoa, Genoa, Italy.
⁴ Hygiene Unit, Policlinico San Martino Hospital-IRCCS, Genoa, Italy.

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adult
Aged
Aged, 80 and over
Antiviral Agents / administration & dosage*
Antiviral Agents / therapeutic use
Betacoronavirus
COVID-19
Coronavirus Infections / drug therapy*
Female
Humans
Hydroxychloroquine / administration & dosage*
Hydroxychloroquine / therapeutic use
Male
Middle Aged
Nasopharynx / virology*
Pandemics
Pneumonia, Viral / drug therapy*
Prospective Studies
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
Treatment Outcome

Substances

Antiviral Agents
Hydroxychloroquine